<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00349622</url>
  </required_header>
  <id_info>
    <org_study_id>U01NS049640-02</org_study_id>
    <secondary_id>NINDS</secondary_id>
    <secondary_id>U01NS049640-02</secondary_id>
    <secondary_id>NINDS CRC</secondary_id>
    <nct_id>NCT00349622</nct_id>
  </id_info>
  <brief_title>Clinical Trial Ceftriaxone in Subjects With ALS</brief_title>
  <official_title>Clinical Trial Ceftriaxone in Subjects With Amyotrophic Lateral Sclerosis (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and efficacy of ceftriaxone treatment in
      amyotrophic lateral sclerosis (ALS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is known that nerve cells called motor neurons die in the brains and spinal cords of
      people with amyotrophic lateral sclerosis (ALS). However, the cause of this cell death is
      unknown. Researchers think that increased levels of a chemical called &quot;glutamate&quot; may be
      related to the cell death. For this reason researchers want to study drugs that decrease
      glutamate levels near nerves. Ceftriaxone—a semi-synthetic, third generation cephalosporin
      antibiotic—may increase the level of a protein that decreases glutamate levels near nerves.
      Studies of ceftriaxone in the laboratory suggest that it may protect motor neurons from
      injury.

      Ceftriaxone is approved by the U.S. Food and Drug Administration (FDA) for treating bacterial
      infections but not for treating ALS. Also, ceftriaxone has not been given to people over a
      long period of time, such as months or years. The goals of this study are to evaluate the
      safety and effectiveness of ceftriaxone as a treatment for ALS, and to determine the safety
      and effectiveness of long-term use of the drug in people with ALS.

      A total of 600 eligible people with ALS will be enrolled in this multi-center research study.
      Participants will be randomly assigned to receive treatment with ceftriaxone (2/3 of
      participants) or placebo (1/3 of participants) for at least 12 months.

      The study consists of three stages. The first stage, which has completed enrollment, will
      look at whether ceftriaxone enters the cerebrospinal fluid (the fluid that surrounds the
      spinal cord, also called CSF) in amounts that are high enough to be of possible benefit. The
      second stage, which has also completed enrollment, will look at the safety and side effects
      of the study drug when taken daily for at least 20 weeks. The study is currently enrolling
      subjects for the third stage, which began in Spring 2009, and will determine whether the
      study drug prolongs survival and slows decline in function due to ALS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>From date of randomization until date of death, tracheostomy, or the initiation of permanent assisted ventilation (PAV). This was assessed at time of each participant's drug discontinuation and every 2 months thereafter for the life of the study (6 yrs)</time_frame>
    <description>Survival is presented as median day of survival for each group. Survival is defined as time to death, tracheostomy or the initiation of permanent assisted ventilation (PAV).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year</measure>
    <time_frame>Every 8 weeks for one year</time_frame>
    <description>Amyotrophic Lateral Sclerosis Functional Rating Scale, Revised (ALSFRS-R) is a quickly administered (five minute) ordinal rating scale used to determine patients' assessment of their capability and independence in 12 functional activities/questions. The 12 functional activities/questions are rated on a scale of 0 to 4 for a total scoring range of 0-48, with 48 representing optimal function. All 12 activities are relevant in ALS.
This outcome measure calculation is based on measurements every 8 weeks from the Baseline Visit up until one year.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in % Vital Capacity From Screening to One Year</measure>
    <time_frame>Every 12 weeks for one Year</time_frame>
    <description>Vital Capacity is measured as the percent predicted per subject based on age, gender, and height, and is performed as a Slow Vital Capacity.
This outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year</measure>
    <time_frame>Every 12 weeks for one Year</time_frame>
    <description>Hand-held Dynamometry (HHD) is used to evaluate muscle strength. Six proximal muscle groups were examined bilaterally in both upper and lower extremities (shoulder flexion, elbow flexion, elbow extension, hip flexion, knee flexion, and knee extension). In addition, wrist extension, first dorsal interosseous contraction and ankle dorsiflexion were measured bilaterally.
HHD analysis was performed using Percent Change from Baseline. Each subject's baseline strength value for each muscle group is considered 100%. During successive visits strength for each muscle group was measured using HHD and was calculated as a percentage of the initial baseline value recorded. Upper extremity and lower extremity values were calculated as the sum of all tests for that extremity to create one megascore for upper and one megascore for lower extremity muscles.
This outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year</measure>
    <time_frame>Every 12 weeks for one Year</time_frame>
    <description>The ALS-Specific Quality of Life Scale (ALSQOL). was developed, tested, and validated in subjects with ALS, and is not a health-related quality of life scale. The scale consists of 59 questions that ask about severity of the symptoms of ALS, mood and affect, intimacy, and social issues. Each question for the ALSQOL is scored from 0-10. With 59 questions, total score ranges from 0-590 with scores simply added, with 590 representing highest quality of life. However since 10 is maximally weighted towards negative values on some questions and positive values on others, the following questions must have results transposed (Simply reverse the scale, for instance 10=0 and 0=10) prior to analysis: 1-10, 11, 16, 19, 24, 26, 28, 32, 35, 36, 38, and 41. Optional items are 50, 53, 56, and 59. These questions are not included on any scale or in any quantitative analyses.
This outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year</measure>
    <time_frame>Every 12 weeks for one Year</time_frame>
    <description>Hand-held Dynamometry (HHD) is used to evaluate muscle strength. Six proximal muscle groups were examined bilaterally in both upper and lower extremities (shoulder flexion, elbow flexion, elbow extension, hip flexion, knee flexion, and knee extension). In addition, wrist extension, first dorsal interosseous contraction and ankle dorsiflexion were measured bilaterally.
HHD analysis was performed using Percent Change from Baseline. Each subject's baseline strength value for each muscle group is considered 100%. During successive visits strength for each muscle group was measured using HHD and was calculated as a percentage of the initial baseline value recorded. Upper extremity and lower extremity values were calculated as the sum of all tests for that extremity to create one megascore for upper and one megascore for lower extremity muscles.
This outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">513</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>ALS</condition>
  <arm_group>
    <arm_group_label>Ceftriaxone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.
Ceftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.
Pediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ceftriaxone</intervention_name>
    <description>Participants will be randomly assigned to receive treatment with ceftriaxone or placebo for at least 12 months. Two thirds of participants will receive ceftriaxone and one third will receive placebo. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.
Ceftriaxone is approved by the U.S. Food and Drug Administration (FDA) for treating bacterial infections but not for treating ALS. Also, ceftriaxone has not been given to people over a long period of time, such as months or years.</description>
    <arm_group_label>Ceftriaxone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>an inactive substance</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants will be people with ALS, at least 18 years of age.

          -  Participants must be medically able to undergo the study procedures and have a
             caregiver or other individual who will be available to help with daily study
             medication administration.

          -  Participants should live within a reasonable distance of the study site, due to
             frequent study visits.

        Exclusion Criteria:

          -  Participants cannot be taking any other experimental medications for ALS, or have a
             history of sensitivity to cephalosporin antibiotics (such as Ancef, Keflex, Ceclor,
             Ceftin, Lorabid, Suprax, or Fortaz).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merit Cudkowicz, MD, MSc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor of Neurology, Harvard Medical School, Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix Neurological Associates</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco- Fresno</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University School of Medicine (CA)</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine - MDA ALS Neuromuscular Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Care</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALS Center at Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Georgia</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Medical School</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University (Regenstrief Health Center)</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Mary's Healthcare</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center (Berman Center)</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bryan LGH Medical Center (University of Nebraska)</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMDNJ- Robert Wood Johnson School of Medicine</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center (NY)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Clinic (Providence Clinic)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania State University, Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drexel University College of Medicine (Hahnemann Campus)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Neurology</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Neurological Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Sciences Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univeristy of Alberta ALS Clinic</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dalhousie University</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Center, University Campus</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM (Centre Hospitalier de l'Université de Montréal), Notre-Dame Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute (McGill University)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laval University</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <link>
    <url>http://www.alsconsortium.org</url>
    <description>Northeast ALS Consortium website</description>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2006</study_first_submitted>
  <study_first_submitted_qc>July 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2006</study_first_posted>
  <results_first_submitted>October 23, 2013</results_first_submitted>
  <results_first_submitted_qc>February 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 1, 2014</results_first_posted>
  <last_update_submitted>April 1, 2014</last_update_submitted>
  <last_update_submitted_qc>April 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Merit E. Cudkowicz, MD</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>amyotrophic lateral sclerosis</keyword>
  <keyword>ALS</keyword>
  <keyword>ceftriaxone</keyword>
  <keyword>cephalosporin antibiotic</keyword>
  <keyword>motor neurons</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftriaxone</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Ceftriaxone is approved by the U.S. Food and Drug Administration (FDA) for treating bacterial infections but not for treating ALS. Subjects with ALS were enrolled in 58 institutions across in the US and Canada.</recruitment_details>
      <pre_assignment_details>Participants were randomly assigned to receive treatment with ceftriaxone or placebo for at least 12 months. Two thirds of participants received ceftriaxone and one third received placebo. This is a blinded study, so neither participants nor study staff knew which treatment a participant is receiving.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ceftriaxone</title>
          <description>Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.
Ceftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.
Pediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="340"/>
                <participants group_id="P2" count="173"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="178"/>
                <participants group_id="P2" count="96"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="168"/>
                <participants group_id="P2" count="86"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ceftriaxone</title>
          <description>Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.
Ceftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.
Pediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="340"/>
            <count group_id="B2" value="173"/>
            <count group_id="B3" value="513"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age at Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.6" spread="10.4"/>
                    <measurement group_id="B2" value="54.8" spread="10.3"/>
                    <measurement group_id="B3" value="55.4" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="209"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="320"/>
                    <measurement group_id="B2" value="165"/>
                    <measurement group_id="B3" value="485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="320"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="293"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ALS Family History</title>
          <description>Subjects were asked at screening whether or not they have a familial history of ALS.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Familial History of ALS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Known Familial History of ALS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="307"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Site of Onset</title>
          <description>Indicates region of first symptoms</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Limb</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="257"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulbar</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Both</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Riluzole Use</title>
          <description>At the screening visit, subjects were asked whether or not they were taking a continuous dose of riluzole.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>On Riluzole</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="249"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not on Riluzole</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vital Capacity Percent Predicted</title>
          <description>The vital capacity (lung capacity) for each subject was measured at screening.</description>
          <units>percent predicted based on age and heigh</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87.9" spread="16.6"/>
                    <measurement group_id="B2" value="91.1" spread="18.4"/>
                    <measurement group_id="B3" value="89.0" spread="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time to Screening</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Years from Symptom Onset to Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.49" spread="0.68"/>
                    <measurement group_id="B2" value="1.50" spread="0.67"/>
                    <measurement group_id="B3" value="1.49" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Years from Diagnosis to Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.56" spread="0.49"/>
                    <measurement group_id="B2" value="0.58" spread="0.49"/>
                    <measurement group_id="B3" value="0.57" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Years from Symptom Onset to Diagnosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.93" spread="0.55"/>
                    <measurement group_id="B2" value="0.92" spread="0.58"/>
                    <measurement group_id="B3" value="0.92" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Survival</title>
        <description>Survival is presented as median day of survival for each group. Survival is defined as time to death, tracheostomy or the initiation of permanent assisted ventilation (PAV).</description>
        <time_frame>From date of randomization until date of death, tracheostomy, or the initiation of permanent assisted ventilation (PAV). This was assessed at time of each participant's drug discontinuation and every 2 months thereafter for the life of the study (6 yrs)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ceftriaxone</title>
            <description>Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.
Ceftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.
Pediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <description>Survival is presented as median day of survival for each group. Survival is defined as time to death, tracheostomy or the initiation of permanent assisted ventilation (PAV).</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="664" lower_limit="614" upper_limit="794"/>
                    <measurement group_id="O2" value="581" lower_limit="521" upper_limit="672"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year</title>
        <description>Amyotrophic Lateral Sclerosis Functional Rating Scale, Revised (ALSFRS-R) is a quickly administered (five minute) ordinal rating scale used to determine patients' assessment of their capability and independence in 12 functional activities/questions. The 12 functional activities/questions are rated on a scale of 0 to 4 for a total scoring range of 0-48, with 48 representing optimal function. All 12 activities are relevant in ALS.
This outcome measure calculation is based on measurements every 8 weeks from the Baseline Visit up until one year.</description>
        <time_frame>Every 8 weeks for one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ceftriaxone</title>
            <description>Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.
Ceftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.
Pediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year</title>
          <description>Amyotrophic Lateral Sclerosis Functional Rating Scale, Revised (ALSFRS-R) is a quickly administered (five minute) ordinal rating scale used to determine patients' assessment of their capability and independence in 12 functional activities/questions. The 12 functional activities/questions are rated on a scale of 0 to 4 for a total scoring range of 0-48, with 48 representing optimal function. All 12 activities are relevant in ALS.
This outcome measure calculation is based on measurements every 8 weeks from the Baseline Visit up until one year.</description>
          <units>units on a scale per 8 weeks</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1311" spread="0.04395"/>
                    <measurement group_id="O2" value="-1.2208" spread="0.06177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in % Vital Capacity From Screening to One Year</title>
        <description>Vital Capacity is measured as the percent predicted per subject based on age, gender, and height, and is performed as a Slow Vital Capacity.
This outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year.</description>
        <time_frame>Every 12 weeks for one Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ceftriaxone</title>
            <description>Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.
Ceftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.
Pediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in % Vital Capacity From Screening to One Year</title>
          <description>Vital Capacity is measured as the percent predicted per subject based on age, gender, and height, and is performed as a Slow Vital Capacity.
This outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year.</description>
          <units>percent change in VC per 12 weeks</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.772" spread="0.1417"/>
                    <measurement group_id="O2" value="-3.0826" spread="0.1970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year</title>
        <description>Hand-held Dynamometry (HHD) is used to evaluate muscle strength. Six proximal muscle groups were examined bilaterally in both upper and lower extremities (shoulder flexion, elbow flexion, elbow extension, hip flexion, knee flexion, and knee extension). In addition, wrist extension, first dorsal interosseous contraction and ankle dorsiflexion were measured bilaterally.
HHD analysis was performed using Percent Change from Baseline. Each subject’s baseline strength value for each muscle group is considered 100%. During successive visits strength for each muscle group was measured using HHD and was calculated as a percentage of the initial baseline value recorded. Upper extremity and lower extremity values were calculated as the sum of all tests for that extremity to create one megascore for upper and one megascore for lower extremity muscles.
This outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year.</description>
        <time_frame>Every 12 weeks for one Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ceftriaxone</title>
            <description>Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.
Ceftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.
Pediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year</title>
          <description>Hand-held Dynamometry (HHD) is used to evaluate muscle strength. Six proximal muscle groups were examined bilaterally in both upper and lower extremities (shoulder flexion, elbow flexion, elbow extension, hip flexion, knee flexion, and knee extension). In addition, wrist extension, first dorsal interosseous contraction and ankle dorsiflexion were measured bilaterally.
HHD analysis was performed using Percent Change from Baseline. Each subject’s baseline strength value for each muscle group is considered 100%. During successive visits strength for each muscle group was measured using HHD and was calculated as a percentage of the initial baseline value recorded. Upper extremity and lower extremity values were calculated as the sum of all tests for that extremity to create one megascore for upper and one megascore for lower extremity muscles.
This outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year.</description>
          <units>Percent change per 12 weeks</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2735" spread="0.2178"/>
                    <measurement group_id="O2" value="-5.5526" spread="0.3040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year</title>
        <description>The ALS-Specific Quality of Life Scale (ALSQOL). was developed, tested, and validated in subjects with ALS, and is not a health-related quality of life scale. The scale consists of 59 questions that ask about severity of the symptoms of ALS, mood and affect, intimacy, and social issues. Each question for the ALSQOL is scored from 0-10. With 59 questions, total score ranges from 0-590 with scores simply added, with 590 representing highest quality of life. However since 10 is maximally weighted towards negative values on some questions and positive values on others, the following questions must have results transposed (Simply reverse the scale, for instance 10=0 and 0=10) prior to analysis: 1-10, 11, 16, 19, 24, 26, 28, 32, 35, 36, 38, and 41. Optional items are 50, 53, 56, and 59. These questions are not included on any scale or in any quantitative analyses.
This outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year.</description>
        <time_frame>Every 12 weeks for one Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ceftriaxone</title>
            <description>Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.
Ceftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.
Pediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year</title>
          <description>The ALS-Specific Quality of Life Scale (ALSQOL). was developed, tested, and validated in subjects with ALS, and is not a health-related quality of life scale. The scale consists of 59 questions that ask about severity of the symptoms of ALS, mood and affect, intimacy, and social issues. Each question for the ALSQOL is scored from 0-10. With 59 questions, total score ranges from 0-590 with scores simply added, with 590 representing highest quality of life. However since 10 is maximally weighted towards negative values on some questions and positive values on others, the following questions must have results transposed (Simply reverse the scale, for instance 10=0 and 0=10) prior to analysis: 1-10, 11, 16, 19, 24, 26, 28, 32, 35, 36, 38, and 41. Optional items are 50, 53, 56, and 59. These questions are not included on any scale or in any quantitative analyses.
This outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year.</description>
          <units>units on a scale per 12 weeks</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5084" spread="0.3297"/>
                    <measurement group_id="O2" value="-3.4401" spread="0.4629"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year</title>
        <description>Hand-held Dynamometry (HHD) is used to evaluate muscle strength. Six proximal muscle groups were examined bilaterally in both upper and lower extremities (shoulder flexion, elbow flexion, elbow extension, hip flexion, knee flexion, and knee extension). In addition, wrist extension, first dorsal interosseous contraction and ankle dorsiflexion were measured bilaterally.
HHD analysis was performed using Percent Change from Baseline. Each subject’s baseline strength value for each muscle group is considered 100%. During successive visits strength for each muscle group was measured using HHD and was calculated as a percentage of the initial baseline value recorded. Upper extremity and lower extremity values were calculated as the sum of all tests for that extremity to create one megascore for upper and one megascore for lower extremity muscles.
This outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year.</description>
        <time_frame>Every 12 weeks for one Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ceftriaxone</title>
            <description>Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.
Ceftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.
Pediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year</title>
          <description>Hand-held Dynamometry (HHD) is used to evaluate muscle strength. Six proximal muscle groups were examined bilaterally in both upper and lower extremities (shoulder flexion, elbow flexion, elbow extension, hip flexion, knee flexion, and knee extension). In addition, wrist extension, first dorsal interosseous contraction and ankle dorsiflexion were measured bilaterally.
HHD analysis was performed using Percent Change from Baseline. Each subject’s baseline strength value for each muscle group is considered 100%. During successive visits strength for each muscle group was measured using HHD and was calculated as a percentage of the initial baseline value recorded. Upper extremity and lower extremity values were calculated as the sum of all tests for that extremity to create one megascore for upper and one megascore for lower extremity muscles.
This outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year.</description>
          <units>Percent change per 12 weeks</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1530" spread="0.2591"/>
                    <measurement group_id="O2" value="-4.4807" spread="0.3625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were systematically assessed by study investigators at each study visit from the screening visit until 30 days after permanent study drug discontinuation. The total amount of time per subject varies by length of subject participation.</time_frame>
      <desc>Adverse Events were systematically assessed by study investigators at each study visit from the screening visit until 30 days after permanent study drug discontinuation.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ceftriaxone</title>
          <description>Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.
Ceftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.
Pediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="276" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood/Bone Marrow - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia (fever of unknown origin w/out clinically/microbiologically documented infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Cardiac/Arrhythmia Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Left ventricular diastolic dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmias: Sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia: Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="340"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Pain: Abdomen NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Gastritis (including bile reflux gastritis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Heartburn/Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Hemmorhage, GI: Lower GI NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Hemmorhage, GI: Stomach</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Obstruction, GI: Ileum</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Obstruction, GI: Stomach</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Pain: Stomach</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death not associated with CTCAE Term: Disease Progression NOS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="340"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term: Death NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Fever (in the absense of neutropenia, where neutropenia is defined as AGC&lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE Term: Sudden Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (3.0) suppl.">Line break/tear</sub_title>
                <description>&quot;Line break/tear&quot; was added to the trial database as an adverse event potentially related to the central venous catheter that all subjects received as part of the study.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (3.0) suppl.">Line Displacement</sub_title>
                <description>&quot;Line Displacement&quot; was added to the trial database as an adverse event potentially related to the central venous catheter that all subjects received as part of the study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (3.0) suppl.">Line Thrombosis</sub_title>
                <description>&quot;Line Thrombosis&quot; was added to the trial database as an adverse event potentially related to the central venous catheter that all subjects received as part of the study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Pain: Chest/thorax NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="30" subjects_affected="28" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Biliary Sludge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Hepatobiliary - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections with unknown ANC: Lung (pneumonia)</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="340"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (3.0) suppl.">Line Infection</sub_title>
                <description>&quot;Line Infection&quot; was added to the trial database as an adverse event potentially related to the central venous catheter that all subjects received as part of the study.</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="340"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or grade 1 or 2 neutrophils: Lung (pneumonia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="340"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (3.0) suppl.">Catheter Exit Site Infection</sub_title>
                <description>&quot;Catheter Exit Site Infection&quot; was added to the trial database as an adverse event potentially related to the central venous catheter that all subjects received as part of the study.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or grade 1 or 2 neutrophils: Blood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Infections with unknown ANC: Blood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Colitis infectious (Clostridium difficile)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC: Urinary tract NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically or microbiologically) with grade 3 or 4 neutropenia: Lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or grade 1 or 2 neutrophils: Bronchus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or grade 1 or 2 neutrophils: Vagina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC: Abdomen NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC: Catheter-related</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC: Foreign body (e.g. graft, implant, prosthesis, stent)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC: Soft tissue NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="340"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Hemmorhage, pulmonary/Upper Respiratory: Stoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Hemorrhage/bleeding associated with surgery, intraoperative or postoperative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Leak (including anastomotic), GI: Stomach</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>FEV (1)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Potassium, serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint-function</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Musculoskeletal - Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Pain: chest wall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Neurology - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Somnolence/depressed level of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Hemmorhage, CNS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Pain: Head/headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration: Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Mood alteration: Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Mood alteration: Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal/Genitourinary - Other</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Stricture/stenosis (including anastomotic), GU: Ureter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Urinary retention (including nerogenic bladder)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Sexual/Reproductive Function - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="79" subjects_affected="74" subjects_at_risk="340"/>
                <counts group_id="E2" events="35" subjects_affected="34" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="340"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Pulmonary - Other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Obstruction/stenosis of airway: Larynx</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Obstruction/stenosis of airway: Trachea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE (3.0) suppl.">PEG Placement (outpatient)</sub_title>
                <description>PEG (Percutaneous Endoscopic Gastrostomy) Placement was added as an adverse event term during STAGES 1 and 2 of this study. PEG tube placements are common for people with ALS. In STAGE 3 of the study, these events were coded as Dysphagia.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="340"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="340"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism (vascular access-related)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="331" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="153" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="20" subjects_at_risk="340"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="220" subjects_affected="152" subjects_at_risk="340"/>
                <counts group_id="E2" events="51" subjects_affected="41" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="76" subjects_affected="66" subjects_at_risk="340"/>
                <counts group_id="E2" events="34" subjects_affected="30" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="115" subjects_affected="64" subjects_at_risk="340"/>
                <counts group_id="E2" events="39" subjects_affected="28" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Dysphagia, (difficult swallowing)</sub_title>
                <counts group_id="E1" events="38" subjects_affected="35" subjects_at_risk="340"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other</sub_title>
                <counts group_id="E1" events="41" subjects_affected="36" subjects_at_risk="340"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Heartburn/Dyspepsia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="24" subjects_at_risk="340"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="33" subjects_affected="24" subjects_at_risk="340"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE (3.0) suppl.">Catheter Exit Site Reaction</sub_title>
                <description>&quot;Catheter Exit Site Reaction&quot; was added to the trial database as an adverse event potentially related to the central venous catheter that all subjects received as part of the study.</description>
                <counts group_id="E1" events="143" subjects_affected="98" subjects_at_risk="340"/>
                <counts group_id="E2" events="69" subjects_affected="45" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Pain: Abdomen NOS</sub_title>
                <counts group_id="E1" events="114" subjects_affected="75" subjects_at_risk="340"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Edema: Limb</sub_title>
                <counts group_id="E1" events="68" subjects_affected="54" subjects_at_risk="340"/>
                <counts group_id="E2" events="25" subjects_affected="22" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="44" subjects_affected="41" subjects_at_risk="340"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Pain: Neck</sub_title>
                <counts group_id="E1" events="37" subjects_affected="34" subjects_at_risk="340"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Fever (absence of neutropenia, where neutropenia is AGC &lt;1.0x10e9/L)</sub_title>
                <counts group_id="E1" events="28" subjects_affected="27" subjects_at_risk="340"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Line break/tear</sub_title>
                <description>&quot;Line break/tear&quot; was added to the trial database as an adverse event potentially related to the central venous catheter that all subjects received as part of the study.</description>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="340"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Pain - Other</sub_title>
                <counts group_id="E1" events="26" subjects_affected="18" subjects_at_risk="340"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="193" subjects_affected="158" subjects_at_risk="340"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Biliary Sludge</sub_title>
                <counts group_id="E1" events="110" subjects_affected="100" subjects_at_risk="340"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Hepatobiliary - Other</sub_title>
                <counts group_id="E1" events="25" subjects_affected="20" subjects_at_risk="340"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="25" subjects_affected="19" subjects_at_risk="340"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" events="64" subjects_affected="42" subjects_at_risk="340"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or grade 1 or 2 neutrophils: Urinary Tract NOS</sub_title>
                <counts group_id="E1" events="29" subjects_affected="25" subjects_at_risk="340"/>
                <counts group_id="E2" events="24" subjects_affected="17" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC: Upper airway NOS</sub_title>
                <counts group_id="E1" events="34" subjects_affected="20" subjects_at_risk="340"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Infection with unkown ANC: Urinary tract NOS</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="340"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising (in absence of grade 3 or 4 thrombocytopenia)</sub_title>
                <counts group_id="E1" events="44" subjects_affected="24" subjects_at_risk="340"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="29" subjects_affected="24" subjects_at_risk="340"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="42" subjects_affected="32" subjects_at_risk="340"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="41" subjects_affected="30" subjects_at_risk="340"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="340"/>
                <counts group_id="E2" events="20" subjects_affected="13" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>AST SGOT (serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="27" subjects_affected="23" subjects_at_risk="340"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="340"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy): Extremity-lower</sub_title>
                <counts group_id="E1" events="61" subjects_affected="46" subjects_at_risk="340"/>
                <counts group_id="E2" events="30" subjects_affected="26" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Pain: Back</sub_title>
                <counts group_id="E1" events="59" subjects_affected="53" subjects_at_risk="340"/>
                <counts group_id="E2" events="22" subjects_affected="17" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Pain: Joint</sub_title>
                <counts group_id="E1" events="62" subjects_affected="47" subjects_at_risk="340"/>
                <counts group_id="E2" events="24" subjects_affected="19" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Musculoskeletal - Other</sub_title>
                <counts group_id="E1" events="57" subjects_affected="45" subjects_at_risk="340"/>
                <counts group_id="E2" events="24" subjects_affected="17" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy): Extremity-upper</sub_title>
                <counts group_id="E1" events="48" subjects_affected="39" subjects_at_risk="340"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Pain: Extremity-limb</sub_title>
                <counts group_id="E1" events="53" subjects_affected="38" subjects_at_risk="340"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Pain: chest wall</sub_title>
                <counts group_id="E1" events="29" subjects_affected="25" subjects_at_risk="340"/>
                <counts group_id="E2" events="17" subjects_affected="12" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized of specific area (not due to neuropathy): Whole body/generalized</sub_title>
                <counts group_id="E1" events="29" subjects_affected="27" subjects_at_risk="340"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurology - Other</sub_title>
                <counts group_id="E1" events="183" subjects_affected="97" subjects_at_risk="340"/>
                <counts group_id="E2" events="92" subjects_affected="52" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Pain: head/headache</sub_title>
                <counts group_id="E1" events="79" subjects_affected="53" subjects_at_risk="340"/>
                <counts group_id="E2" events="37" subjects_affected="32" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Drooling</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="340"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="32" subjects_affected="25" subjects_at_risk="340"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Voice changes/dysarthria (e.g., hoarseness, loss or alteration of voice, laryngitis)</sub_title>
                <counts group_id="E1" events="27" subjects_affected="25" subjects_at_risk="340"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="42" subjects_affected="40" subjects_at_risk="340"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Mood alteration: Depression</sub_title>
                <counts group_id="E1" events="33" subjects_affected="33" subjects_at_risk="340"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Mood alteration: Anxiety</sub_title>
                <counts group_id="E1" events="38" subjects_affected="34" subjects_at_risk="340"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal/Genitourinary - Other</sub_title>
                <counts group_id="E1" events="57" subjects_affected="37" subjects_at_risk="340"/>
                <counts group_id="E2" events="20" subjects_affected="13" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Urinary frquency/urgency</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="340"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="38" subjects_affected="32" subjects_at_risk="340"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Pulmonary - Other</sub_title>
                <counts group_id="E1" events="57" subjects_affected="46" subjects_at_risk="340"/>
                <counts group_id="E2" events="25" subjects_affected="20" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="48" subjects_affected="41" subjects_at_risk="340"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip)</sub_title>
                <counts group_id="E1" events="25" subjects_affected="23" subjects_at_risk="340"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="122" subjects_affected="92" subjects_at_risk="340"/>
                <counts group_id="E2" events="36" subjects_affected="29" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Dermatology/Skin - Other</sub_title>
                <counts group_id="E1" events="78" subjects_affected="57" subjects_at_risk="340"/>
                <counts group_id="E2" events="25" subjects_affected="21" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Pruritis/itching</sub_title>
                <counts group_id="E1" events="41" subjects_affected="33" subjects_at_risk="340"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="22" subjects_affected="16" subjects_at_risk="340"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Merit Cudkowicz</name_or_title>
      <organization>MGH</organization>
      <phone>617-724-1873</phone>
      <email>mcudkowicz@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

